Analyst consensus rating
Cellectar Biosciences Analyst Rating: none
Direct answer
Cellectar Biosciences's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $11.50.
Forecast evidence checked November 9, 2026.
Get free Cellectar Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.25
- Average price target
- $11.50
- High price target
- $15.00
- Low price target
- $10.00
- Low target gap
- +700%
- Target upside
- +820%
- High target gap
- +1,100%
- Target range width
- 400%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- November 9, 2026
- Valid through
- November 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cellectar Biosciences?
Cellectar Biosciences has a verified none consensus. The same dataset has an average price target of $11.50.
How far are Cellectar Biosciences's low and high targets from the recorded price?
The low target implies +700%, while the high target implies +1,100%.
How many analysts are included in Cellectar Biosciences's consensus?
The verified consensus includes 4 analysts.
How is Cellectar Biosciences's target upside or downside calculated?
The average target of $11.50 is divided by the recorded price of $1.25, then one is subtracted to produce +820%. This does not guarantee a future return.
When was Cellectar Biosciences's analyst forecast verified?
The data was verified on 2026-11-09. The dataset is valid through 2026-11-16.